In the midst of a global COVID-19 pandemic, a top priority for many pharma and biopharma companies is to get a vaccine developed, produced and delivered to the public as quickly as possible. Ushering a vaccine through rigorous testing protocols and regulatory approvals is not an easy (or quick) effort, but incorporating advanced data analytics could help accelerate the process. Data analytics has proven effective in speeding vaccine development both by enabling more efficient Design of Experiments (DOE) and by creating rapid-scale production rollout processes.
Looking for ways to improve the efficiency of its power plant operations while reducing costs and environmental emissions, the Department of Power and Water at Michigan State University (MSU) began a study using multivariate data analytics that led to some surprising findings. The results have implications that could help other operators of large-scale power facilities reduce their carbon footprint and improve power plant operations.
Finding the right balance between efficient power output from boilers and other energy producing equipment while also reducing environmental emissions is an important objective for power plant operators. Governments and environmental agencies around the world establish emission standards as part of air pollution regulations, but finding the right way to meet the standards can vary greatly depending on location, equipment and other operating factors.
While many other industries have implemented multivariate data analysis software for process optimization and control, it is still not very common in the pulp and paper industry. However, multivariate data analysis has a very promising potential for both cost reductions and quality improvements in pulp and paper mills. No capital investments are needed, the implementation can be done remotely, and the software typically requires no permits.
Optimizing the function of boilers, turbines and other capital equipment used to generate power requires a careful balance of fuel, heat, pressure, operator proficiency and many other variables. Managing the process on a day-to-day, or minute-to-minute basis, is like performing a skilled and well-orchestrated dance—partly based on data, but also based on operator expertise. Yet, adding more accurate information to the equation can potentially save millions of dollars, cut emissions significantly and even expand the working life of your equipment.
There is a strong demand for devices such as mobile phones, tablets and large screen TVs all over the globe. The business is competitive, which puts pressure on prices. At the same time, production costs are fairly high due to complex production processes. Consequently, a high yield becomes paramount for good profit margins. Multivariate data analysis (MVDA) is being employed by an increasing number of manufacturing companies to increase yield, and the electronics industry is no exception. This article provides examples of where and how real-time data analytics can be used in the electronics industry.
The pharmaceutical industry, including R&D, manufacturing and also product sales and use, creates a lot of data. The question is, what can we do to understand our data better, get more out of it, and unlock its potential in the most rational way possible to get to the knowledge we need? And how can we gain control over our research, or the processes needed to generate a stable, reliable product that consistently meets regulatory requirements? The answer is Multivariate Data Analysis.
The potential for Artificial Intelligence (AI) is enormous and the applications seemingly unlimited. One subset of AI, deep learning, offers the promise of efficiently solving a large range of challenges involving unstructured data by harnessing neural networks to save time and money, and even perform seemingly impossible tasks.
Deep learning has revolutionized the fields of artificial intelligence, computer vision, speech recognition, and more in recent years. Deep learning can draw information from unstructured data such as images or text in a way that was unthinkable a decade ago. In industries like Pharma and Biopharma, deep learning can help all the way from understanding how cells work using live cell imaging to monitoring manufacturing using audio.
Whether it’s fake olive oil, coffee bulked up with husks and twigs, or honey tainted with antibiotics, food fraud is a growing problem worldwide. The Australian research organization CSIRO states that the economic damage alone from food fraud has reached $35 billion (in US dollars) in 2018. The underlying cause is nearly always financial gain and economic pressures to save money by using inferior (or mislabeled) products. Predictive analytics is one tool manufacturers are using to combat food fraud.
SIMCA 16 offers improved ribbons, tours, wizards, data merging, multiblock analysis and more.
SIMCA is a multivariate data analytics tool that helps users make sense of complex data by transforming numbers and statistics into visual information for easy interpretation and understanding. Across many industries ranging from pharmaceuticals and chemicals to food and beverage manufacturers to academia, SIMCA helps production managers and researchers a like make better decisions in order to take action quickly and with confidence.
Recently the FDA issued a new draft guidance for continuous manufacturing of small molecule drugs. With these draft guidelines the FDA wants to engage more pharmaceutical manufacturers to shift from traditional batch/start-stop processing to continuous manufacturing. The main advantages associated with these processes are more room for modularity, automation and flexibility due to a smaller footprint, but also more consistent quality of the drug product. Of course the main incentive for the FDA to promote this way of processing is that it believes that this will have a positive impact on drug prices and prevent drug shortages.
Breast cancer is the most commonly diagnosed cancer amongst women worldwide and a leading cause of cancer related deaths among females. It’s the second most common type of cancer overall. According to the International Agency for Research on Cancer Research, there were more than 2 million new cases in 2018.